secwatch.observer — SEC 8-K summary
======================================

Issuer:     Travere Therapeutics, Inc. (TVTX)
CIK:        0001438533
Form:       8-K
Filed at:   2023-11-07T23:59:59+00:00
Accession:  0001438533-23-000046
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Travere Q3 net income $150.7M from bile acid sale; FILSPARI sales $8M, 430 new starts
--------------------------------------------------------------------------------

- Net income $150.7M ($1.97/share) includes gain from bile acid portfolio sale; prior year loss $69.7M.
- FILSPARI net sales $8.0M in Q3, 430 new patient start forms (990 total since Feb 2023 launch).
- R&D expense $60.6M, SG&A $67.8M; cash, equivalents & marketable securities $634.6M.
- Regulatory: on track for sNDA for FILSPARI in IgAN (full approval) & FSGS in Q4; EU CHMP opinion year-end.
- Completed sale of bile acid products to Mirum for up to $445M; pegtibatinase pivotal study to start by year-end.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1438533/000143853323000046/0001438533-23-000046-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1438533/000143853323000046/tvtx-20231107.htm
  HTML page:      https://secwatch.observer/filing/0001438533-23-000046

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer